Patents by Inventor Liewei Wang
Liewei Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250095177Abstract: A method and a system for automatically collecting multiple information of a tunnel during construction period are provided. A detection point and a detection line are formed by projecting a light source on the inner wall of the tunnel, and then the pixel position changes of the areas where the detection point and the detection line are located in different time periods are recorded by a measuring camera, and the detection point and the detection line are integrated and corrected with tunnel point cloud data as a reference standard to form an accurate four-dimensional model of the tunnel.Type: ApplicationFiled: November 22, 2024Publication date: March 20, 2025Inventors: Siming TIAN, Zhengying SHI, Weike XIN, Shu LI, Jianxun HUO, Liewei WANG, Jie LIAN, Guangbin NI, Guoqiang WU, Xinyan WU, Xu LI, Yiteng ZHANG
-
Publication number: 20250006332Abstract: Likely outcomes of a treatment of an adolescent patient who has major depressive disorder (“MDD”) using machine learning. Symptoms reported at one or two points in time are input to a suitably trained machine learning model, generating output that indicate a prediction of the most likely outcome of a particular treatment at a third point in time, a future severity of symptoms, or another clinical course of action. The treatment outcome can include the likelihood of remission, response to drug, selection of the drug most likely to give positive outcomes, and so on. The machine learning model can implement a probabilistic graphical model, as an example.Type: ApplicationFiled: September 8, 2022Publication date: January 2, 2025Inventors: Arjun P. Athreya, William V. Bobo, Liewei Wang, Richard M. Weinshilboum, Paul E. Croarkin
-
Publication number: 20240307414Abstract: This document relates to methods and materials for assessing and/or treating mammals (e.g., humans) having prostate cancer. For example, methods and materials for determining whether or not a prostate cancer is likely to respond to a particular cancer treatment (e.g., an anti-androgen agent) are provided. Methods and materials for using one or more cancer treatments to treat a mammal (e.g., a human) identified as likely to respond to a particular cancer treatment are also provided.Type: ApplicationFiled: December 21, 2021Publication date: September 19, 2024Inventors: Liewei Wang, Huanyao Gao
-
Patent number: 11908121Abstract: Provided are a method and a device for real-time monitoring of tunnel deformation. The monitoring method includes: S1, erecting a plurality of structured light sources in an unstable area to be monitored of a tunnel structure, and erecting a monitoring terminal in a relatively stable region of the tunnel structure, where the monitoring terminal may communicate with the plurality of structured light sources; S2, observing all structured lights in the unstable area of the tunnel structure and obtaining structured light curves in real time by the monitoring terminal; S3, analyzing imaging changes of the structured lights, detecting deformation degrees and offset distances of the tunnel in real time, and monitoring the diseases such as settlement, convergence of a single-section of the tunnel and integral settlement of a multi-section of the tunnel by the data processing unit.Type: GrantFiled: August 8, 2023Date of Patent: February 20, 2024Assignee: NANJING PIONEER AWARENESS INFORMATION TECHNOLOGY CO., LTDInventors: Zhengying Shi, Weike Xin, Shu Li, Liewei Wang, Jie Lian, Youqun Huang, Haidong Lu, Yang Li, Peiyao Li, Guoqiang Wu, Baoqian Xia
-
Patent number: 11865163Abstract: This document provides methods and materials for using butyrylcholinesterases (BChE) to treat cancer (e.g., triple negative breast cancer or prostate cancer). For example, methods and materials for using nucleic acid vectors (e.g., viral vectors) to express BChE polypeptides under conditions that reduce the number of cancer cells (e.g., triple negative breast cancer cells or prostate cancer cells) within a mammal (e.g., a human) and/or reduce the growth rate of cancer cells (e.g., triple negative breast cancer cells or prostate cancer cells) within a mammal (e.g., a human) are provided.Type: GrantFiled: September 15, 2017Date of Patent: January 9, 2024Assignee: Mayo Foundation for Medical Education and ResearchInventors: William S. Brimijoin, Liewei Wang, Yang Gao, Ping Chen, Liyi Geng, Jia Yu, Judy C. Boughey, Matthew P. Goetz
-
Patent number: 11869633Abstract: The present disclosure provides methods for accurately predicting the dynamics of symptom response to drugs or other interventions for the treatment of major depressive disorder or other psychological conditions. These methods can allow for a shortening of the time period necessary for the evaluation of a drug or other therapeutic intervention. These predictive methods are based on measured and/or self-reported symptom severity measures at two or more points in time. These measures are then discretized into symptom classes (e.g., low, moderate, severe) and the symptom classes are then applied to the predictive model to predict the progression of symptoms and/or the effectiveness of a drug or other therapeutic intervention.Type: GrantFiled: December 14, 2018Date of Patent: January 9, 2024Assignee: The Board of Trustees of the University of IllinoisInventors: Ravishankar Krishnan Iyer, Arjun Prasanna Athreya, Richard Merle Weinshilboum, Liewei Wang, William Victor Bobo, Mark Andrew Frye
-
Publication number: 20230386006Abstract: Provided are a method and a device for real-time monitoring of tunnel deformation. The monitoring method includes: S1, erecting a plurality of structured light sources in an unstable area to be monitored of a tunnel structure, and erecting a monitoring terminal in a relatively stable region of the tunnel structure, where the monitoring terminal may communicate with the plurality of structured light sources; S2, observing all structured lights in the unstable area of the tunnel structure and obtaining structured light curves in real time by the monitoring terminal; S3, analyzing imaging changes of the structured lights, detecting deformation degrees and offset distances of the tunnel in real time, and monitoring the diseases such as settlement, convergence of a single-section of the tunnel and integral settlement of a multi-section of the tunnel by the data processing unit.Type: ApplicationFiled: August 8, 2023Publication date: November 30, 2023Inventors: Zhengying SHI, Weike XIN, Shu LI, Liewei WANG, Jie LIAN, Youqun HUANG, Haidong LU, Yang LI, Peiyao LI, Guoqiang WU, Baoqian XIA
-
Patent number: 11497729Abstract: This document provides methods and materials involved in treating cancer. For example, methods and materials for using an inhibitor of USP7 polypeptide to increase the sensitivity of cancer cells (e.g., CD340+ cancer cells such as HER2+ cancer cells) to treatment with an inhibitor of a CD340 polypeptide (e.g., an inhibitor of a HER2 polypeptide) are provided. Methods and materials for using USP7 polypeptide inhibitors in combination with CD340 polypeptide inhibitors to treat cancer (e.g., HER2+ breast cancer that was refractory to trastuzumab alone treatment) are provided.Type: GrantFiled: July 7, 2017Date of Patent: November 15, 2022Assignee: Mayo Foundation for Medical Education and ResearchInventors: Liewei Wang, Matthew P. Goetz, Judy C. Boughey, Jia Yu, Bo Qin
-
Patent number: 11122997Abstract: Materials and methods for treating major depressive disorder by modulating the aryl hydrocarbon receptor system are provided herein.Type: GrantFiled: April 15, 2016Date of Patent: September 21, 2021Assignees: Mayo Foundation for Medical Education and Research, Ixcela Inc., Duke UniversityInventors: Balmiki Ray, Liewei Wang, Joanna Biernacka, Mark Frye, Richard M. Weinshilboum, Michiaki Kubo, Taisei Mushiroda, Wayne R. Matson, Rima Kaddurah-Daouk
-
Publication number: 20210283101Abstract: This document provides methods and materials involved in treating cancer. For example, methods and materials for using an inhibitor of USP7 polypeptide to increase the sensitivity of cancer cells (e.g., CD340+ cancer cells such as HER2+ cancer cells) to treatment with an inhibitor of a CD340 polypeptide (e.g., an inhibitor of a HER2 polypeptide) are provided. Methods and materials for using USP7 polypeptide inhibitors in combination with CD340 polypeptide inhibitors to treat cancer (e.g., HER2+ breast cancer that was refractory to trastuzumab alone treatment) are provided.Type: ApplicationFiled: July 7, 2017Publication date: September 16, 2021Applicant: Mayo Foundation for Medical Education and ResearchInventors: Liewei Wang, Matthew P. Goetz, Judy C. Boughey, Jia Yu, Bo Qin
-
Patent number: 10815534Abstract: This document provides methods and materials for treating cancer (e.g., estrogen receptor positive breast cancer). For example, methods and materials for identifying a mammal (e.g., a human) with cancer (e.g., estrogen receptor positive breast cancer) as having A?G variant genotype of rs6990851 and/or as having an elevated level of CSMD1 nucleic acid expression and administering one or more aromatase inhibitors (e.g., anastrozole) to treat the mammal identified as having such genotype and/or elevated level are provided.Type: GrantFiled: August 22, 2017Date of Patent: October 27, 2020Assignee: Mayo Foundation for Medical Education and ResearchInventors: Tanda T. Dudenkov, Liewei Wang, James N. Ingle, Richard M. Weinshilboum, Junmei Cairns
-
Publication number: 20190255154Abstract: This document provides methods and materials for using butyrylcholinesterases (BChE) to treat cancer (e.g., triple negative breast cancer or prostate cancer). For example, methods and materials for using nucleic acid vectors (e.g., viral vectors) to express BChE polypeptides under conditions that reduce the number of cancer cells (e.g., triple negative breast cancer cells or prostate cancer cells) within a mammal (e.g., a human) and/or reduce the growth rate of cancer cells (e.g., triple negative breast cancer cells or prostate cancer cells) within a mammal (e.g., a human) are provided.Type: ApplicationFiled: September 15, 2017Publication date: August 22, 2019Applicant: Mayo Foundation for Medical Education and ResearchInventors: William S. Brimijoin, Liewei Wang, Yang Gao, Ping Chen, Liyi Geng, Jia Yu, Judy C. Boughey, Matthew P. Goetz
-
Publication number: 20190194761Abstract: This document provides methods and materials for treating cancer (e.g., estrogen receptor positive breast cancer). For example, methods and materials for identifying a mammal (e.g., a human) with cancer (e.g., estrogen receptor positive breast cancer) as having A?G variant genotype of rs6990851 and/or as having an elevated level of CSMD1 nucleic acid expression and administering one or more aromatase inhibitors (e.g., anastrozole) to treat the mammal identified as having such genotype and/or elevated level are provided.Type: ApplicationFiled: August 22, 2017Publication date: June 27, 2019Applicant: Mayo Foundation for Medical Education and ResearchInventors: Tanda T. Dudenkov, Liewei Wang, James N. Ingle, Richard M. Weinshilboum, Junmei Cairns
-
Publication number: 20190189247Abstract: The present disclosure provides methods for accurately predicting the dynamics of symptom response to drugs or other interventions for the treatment of major depressive disorder or other psychological conditions. These methods can allow for a shortening of the time period necessary for the evaluation of a drug or other therapeutic intervention. These predictive methods are based on measured and/or self-reported symptom severity measures at two or more points in time. These measures are then discretized into symptom classes (e.g., low, moderate, severe) and the symptom classes are then applied to the predictive model to predict the progression of symptoms and/or the effectiveness of a drug or other therapeutic intervention.Type: ApplicationFiled: December 14, 2018Publication date: June 20, 2019Applicants: The Board of Trustees of the University of Illinois, Mayo Foundation for Medical Education and ResearchInventors: Ravishankar K. Iyer, Arjun Prasanna Athreya, Richard Merle Weinshilboum, Liewei Wang, William Victor Bobo, Mark Andrew Frye
-
Patent number: 10220016Abstract: This document provides methods and materials involved in assessing chemotherapy responsiveness and treating cancer (e.g., breast cancer). For example, methods and materials for determining whether or not a cancer patient (e.g., a breast cancer patient) is likely to respond to chemotherapy (e.g., a taxane therapy) based at least in part on the presence of a variant in the mammal's polycystic kidney disease gene 1 (PKD1) are provided. In addition, methods and materials involved in treating mammals having cancer (e.g., breast cancer) by administering an inhibitor of ubiquitin specific peptidase 2 (USP2) polypeptide activity (e.g., NSC-632839, a 2-cyano-pyrimidine, or a 2-cyano-triazine) in combination with another chemotherapeutic agent such as a taxane therapy are provided.Type: GrantFiled: February 17, 2016Date of Patent: March 5, 2019Assignee: Mayo Foundation for Medical Education and ResearchInventors: Matthew P. Goetz, Judy C. Boughey, Liewei Wang, Krishna R. Kalari, Richard M. Weinshilboum, Vera J. Suman
-
Publication number: 20180098722Abstract: Materials and methods for treating major depressive disorder by modulating the aryl hydrocarbon receptor system are provided herein.Type: ApplicationFiled: April 15, 2016Publication date: April 12, 2018Applicants: Mayo Foundation for Medical Education and Research, Ixcela Inc., Duke UniversityInventors: Balmiki Ray, Liewei Wang, Joanna Biernacka, Mark Frye, Richard M. Weinshilboum, Michiaki Kubo, Taisei Mushiroda, Wayne R. Matson, Rima Kaddurah-Daouk
-
Publication number: 20180021295Abstract: This document provides methods and materials involved in assessing chemotherapy responsiveness and treating cancer (e.g., breast cancer). For example, methods and materials for determining whether or not a cancer patient (e.g., a breast cancer patient) is likely to respond to chemotherapy (e.g., a taxane therapy) based at least in part on the presence of a variant in the mammal's polycystic kidney disease gene 1 (PKD1) are provided. In addition, methods and materials involved in treating mammals having cancer (e.g., breast cancer) by administering an inhibitor of ubiquitin specific peptidase 2 (USP2) polypeptide activity (e.g., NSC-632839, a 2-cyano-pyrimidine, or a 2-cyano-triazine) in combination with another chemotherapeutic agent such as a taxane therapy are provided.Type: ApplicationFiled: February 17, 2016Publication date: January 25, 2018Applicant: Mayo Foundation for Medical Education and ResearchInventors: Matthew P. Goetz, Judy C. Boughey, Liewei Wang, Krishna R. Kalari, Richard M. Weinshilboum, Vera J. Suman
-
Publication number: 20120021920Abstract: Materials and methods related to using biomarkers for prediction of response to radiation therapy.Type: ApplicationFiled: April 1, 2010Publication date: January 26, 2012Applicant: Mayo Foundation for Medical Education and ResearchInventors: Liewei Wang, Richard M. Weinshilboum, Krishna Kalari, Brooke L. Fridley, Yu Xin Qin
-
Patent number: 7858306Abstract: Isolated HSD3B1 nucleic acid molecules that include a nucleotide sequence variant and nucleotides flanking the sequence variant are described, as are HSD3B1 allozymes. Methods for determining whether a subject contains an HSD3B1 sequence variant also are provided.Type: GrantFiled: July 7, 2006Date of Patent: December 28, 2010Assignee: Mayo Foundation for Medical Education and ResearchInventors: Richard M. Weinshilboum, Linda L. Pelleymounter, Eric D. Wieben, Oreste Salavaggione, Liewei Wang
-
Publication number: 20100311606Abstract: Materials and methods for evaluating cellular response to therapeutic agents.Type: ApplicationFiled: May 7, 2008Publication date: December 9, 2010Inventors: Liewei Wang, Richard M. Weinshilboum, Liang Li, Brooke L. Fridley, Krishna Kalari, Daniel Schaid, Matthew M. Ames